All Title Author
Keywords Abstract

A Case of Ectopic Growth Hormone Releasing Hormone (GHRH) from Pancreatic Neuroendocrine Tumor Resistant to Therapy

DOI: 10.4236/ojemd.2013.37037, PP. 271-275

Keywords: Ectopic GHRH, Acromegaly, Pancreatic Neuroendocrine Tumor

Full-Text   Cite this paper   Add to My Lib


Introduction: Ectopic secretion of GHRH is a rare cause of acromegaly. However, its recognition is clinically important because different therapeutic approaches are required. Case Presentation: We present a challenging case of acromegaly secondary to ectopic GHRH secretion from pancreatic neuroendocrine tumor in a 52-year-old female. The patient is treated with different modalities which include pegvisomant in an attempt to control the stimulated GH-axis considering the limited data about its use in treatment of ectopic acromegaly. Conclusion: GHRH-secreting tumor is a rare cause of acromegaly. Surgical resection of the tumor is the therapy of choice whenever possible. However, further studies are warranted for unresectable tumor or resistant cases.


[1]  E. Verrua, C. L. Ronchi, E. Ferrante, et al., “Acromegaly Secondary to an Incidentally Discovered Growth-Hor- mone-Releasing Hormone Secreting Bronchial Carcinoid Tumour Associated to a Pituitary Incidentaloma,” Pituitary, Vol. 13, No. 3, 2010, pp. 289-292.
[2]  D. C. Metz and R. T. Jensen, “Gastrointestinal Tumors: Pancreatic Endocrine Tumors,” Gastroenterology, Vol. 135, No. 5, 2008, pp. 1469-1492.
[3]  M. H. Kulke, L. B. Anthony, D. L. Bushnell, et al., “WellDifferentiated Neuroendocrine Tumors of the Stomach and Pancreas,” Pancreas, Vol. 39, No. 6, 2010, pp. 735-752.
[4]  R. T. Jensen, M. J. Berna, D. B. Bingham, et al., “Inherited Pancreatic Endocrine Tumor Syndromes: Advances in Molecular Pathogenesis, Diagnosis, Management and Controversies,” Cancer, Vol. 113, Suppl. 7, 2008, pp. 1807-1843.
[5]  F. Ehehalt, H. D. Saeger, C. M. Schmidt, et al., “Neuroendocrine Tumors of the Pancreas,” The Oncologist, Vol. 14, No. 5, 2009, pp. 456-467.
[6]  S. Ezziddin, T. Logvinski, C. Yong-Hing, et al., “Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors,” Journal of Nuclear Medicine, Vol. 47, No. 2, 2006, pp. 223-233.
[7]  L. V. Neto, G. F. Taboada, L. L. Corrêa, et al., “Acromegaly Secondary to Growth Hormone-Releasing Hormone Secreted by an Incidentally Discovered Pheochromocytoma,” EndoChoice Pathology, Vol. 18, No. 1, 2007, pp. 46-52.
[8]  Y. Shintani, K. Yoshimoto, H. Horie, et al., “Two Different Pituitary Adenomas in a Patient with Multiple Endocrine Neoplasia Type 1 Associated with Growth Hormone-Releasing Hormone-Producing Pancreatic Tumor: Clinical and Genetic Features,” Endocrine Journal, Vol. 42, No. 3, 1995, pp. 331-340.
[9]  D. Zimmerman, W. F. Young Jr., M. J. Ebersold, et al., “Congenital Gigantism Due to Growth Hormone-Releasing Hormone Excess and Pituitary Hyperplasia with Adenomatous Transformation,” JCEM, Vol. 76, No. 1, 1993, pp. 216-222.
[10]  S. L. Asa, K. Kovacs, L. Stefaneanu, et al., “Pituitary Adenomas in Mice Transgenic for Growth Hormone-Releasing Hormone,” Endocrinology, Vol. 131, No. 5, 1992, pp. 2083-2089.
[11]  R. V. Lloyd, L. Jin, A. Chang, et al., “Morphologic Effects of hGRH Gene Expression on the Pituitary, Liver, and Pancreas of MT-hGRH Transgenic Mice. An in Situ Hybridization Analysis,” American Journal of Pathology, Vol. 141, No. 4, 1992, pp. 895-906.
[12]  J. Rivier, J. Spiess, M. Thorner, et al., “Characterization of a Growth Hormone-Releasing Factor from a Human Pancreatic Islet Tumor,” Nature, Vol. 300, No. 5889, 1982, pp. 276-278.
[13]  H. Kiaris, M. Koutsilieris, A. Kalofoutis, et al., “Growth Hormone-Releasing Hormone and Extra-Pituitary Tu- morigenesis: Therapeutic and Diagnostic Applications of Growth Hormone-Releasing Hormone Antagonists,” Ex- pert Opinion on Investigational Drugs, Vol. 12, No. 8, 2003, pp. 1385-1394.
[14]  A. Plonowski, A. V. Schally, M. Letsch, et al., “Inhibition of Proliferation of PC-3 Human Prostate Cancer by Antagonists of Growth Hormone-Releasing Hormone: Lack of Correlation with the Levels of Serum IGF-I and Expression of Tumoral IGF-II and Vascular Endothelial Growth Factor,” Prostate, Vol. 52, No. 3, 2002, pp. 173-182.
[15]  A. Plonowski, J. L. Vagra, A. V. Schally, et al., “Inhibition of PC-3 Human Prostate Cancers by Analogs of Growth Hormone-Releasing Hormone (GH-RH) Endowed with Vasoactive Intestinal Peptide (VIP) Antagonistic Activity,” International Journal of Cancer, Vol. 98, No. 4, 2002, pp. 624-629.
[16]  I. Chatzistamoul, A. V. Schally, J. L. Vagra, et al., “Inhibition of Growth and Metastases of MDA-MB-435 Human Estrogen-Independent Breast Cancers by an Antagonist of Growth Hormone-Releasing Hormone,” Anticancer Drugs, Vol. 12, No. 9, 2001, pp. 761-768.
[17]  N. Barabutis and A. V. Schally, “Growth Hormone-Releasing Hormone: Extrapituitary Effects in Physiology and Pathology,” Cell Cycle, Vol. 9, No. 20, 2010, pp. 4110-4116.
[18]  M. Doga, S. Bonadonna, A. Burattin, et al., “Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH) in Neuroendocrine Tumors: Relevant Clinical Aspects,” Annals of Oncology, Vol. 12, Suppl. 2, 2001, pp. S89S94.
[19]  C. Jaffe, R. DeMott-Friberg, L. Frohman, et al., “Suppression of Growth Hormone Hypersecretion Due to Ectopic GHRH by Selective GHRH Antagonist,” JCEM, Vol. 82, No. 2, 1997, pp. 634-637.
[20]  M. Gola, M. Doga, S. Bonadonna, et al., “Neuroendocrine Tumors Secreting Growth Hormone-Releasing Hormone,” Pituitary, Vol. 9, No. 3, 2006, pp. 221-229.
[21]  L. A. Frohman, T. R. Downs, T. C. Williams, et al., “Rapid Enzymatic Degradation of Growth Hormone-Releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH2 Terminus,” Journal of Clinical Investigation, Vol. 78, No. 4, 1986, pp. 906-913.
[22]  N. H. Othman, S. Ezzat, K. Kovacs, et al., “Growth Hormone-Releasing Hormone (GHRH) and GHRH Receptor (GHRH-R) Isoform Expression in Ectopic Acromegaly,” Clinical Endocrinology, Vol. 55, No. 1, 2001, pp. 135-140.
[23]  L. Szalontay, R. J. Benveniste, A. V. Schally, et al., “Inhibitory Effects of GHRH Antagonists on Human GHSecreting Adenoma Tissue,” Neuroendocrinology, Vol. 96, No. 1, 2012, pp. 81-88.
[24]  M. C. Zatelli, D. Piccin, F. Tagliati, et al., “Somatostatin Receptor Subtype 1 Selective Activation in Human Growth Hormone (GH) and Prolactin (PRL) Secreting Pituitary Adenomas: Effects on Cell Variability, GH, and PRL Secretion,” JCEM, Vol. 88, No. 6, 2003, pp. 2797-2802.
[25]  G. Sassolas and J. A. Chayvialle, “GRFomas, Somatostati- nomas: Clinical Presentation, Diagnosis and Advances in Management,” In: M. Mignon and R. T. Jensen, Eds., Endocrine Tumors of the Pancreas: Recent Advances in Research and Management, Vol. 23, Basel, Karger, 1995, pp. 194-207.
[26]  D. E. Weiss, H. Vogel, M. B. S. Lopes, et al., “Ectopic Acromegaly Due to a Pancreatic Neuroendocrine Tumor Producing Growth Hormone Releasing Hormone,” Endocrine Practice, Vol. 17, No. 1, 2011, pp. 79-84.
[27]  A. Agha, L. Farrell, P. Downey, et al., “Acromegaly Secondary to Growth Hormone Releasing Hormone Secretion,” Irish Journal of Medical Science, Vol. 173, No. 4, 2004, pp. 215-216.
[28]  L. Garby, P. Caron, F. Claustrat, et al., “Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases,” JCEM, Vol. 97, No. 6, 2012, pp. 2093-2104.


comments powered by Disqus